Insomnia symptoms and subclinical myocardial injury : Data from the Nord‐Trøndelag Health (HUNT) study
Summary Insomnia symptoms are associated with increased risk of heart failure (HF) and cardiovascular (CV) mortality. We hypothesised that insomnia symptoms are cross‐sectionally associated with increased cardiac troponin I (cTnI), a biomarker of subclinical myocardial injury, and that phenotyping by insomnia symptoms and cTnI enhances longitudinal risk stratification in the general population. In a population‐based study, cTnI was measured in 8,398 participants (median age 49 years, 55% women), who had answered questionnaires regarding insomnia symptoms. Association between cTnI and insomnia symptoms was assessed by linear regression analysis for each response category of a sleep questionnaire. Insomnia symptoms were defined as having difficulty falling asleep almost every night, difficulty maintaining sleep almost every night, and/or non‐restorative sleep once a week or more. The primary outcome measure was a composite endpoint of CV mortality or first admission for HF. In all, 844 participants reported insomnia symptoms, 585 (69%) were women. Those with insomnia symptoms had marginally, but significantly higher median cTnI than those without insomnia symptoms, (median [interquartile range] 3.4 [2.4–5.2] ng/L versus 3.2 [2.2–4.9] ng/L; p = .014), but there was no association between any insomnia symptom and cTnI in unadjusted linear regression models (β 0.06, 95% confidence interval [CI] −0.01 to 0.12). In adjusted analyses, participants with insomnia symptoms and increased cTnI were at increased risk of the composite endpoint (hazard ratio 1.71, 95% CI 1.04–2.79) compared to participants with insomnia symptoms and low cTnI. In the general population, insomnia symptoms are not associated with biochemical evidence of subclinical myocardial injury..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Journal of Sleep Research - 30(2021), 5 |
| Beteiligte Personen: |
Sigurdardottir, Fjola D. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 European Sleep Research Society |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1111/jsr.13299 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY009506993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY009506993 | ||
| 003 | DE-627 | ||
| 005 | 20230307190231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/jsr.13299 |2 doi | |
| 028 | 5 | 2 | |a JSR_JSR13299.xml |
| 035 | |a (DE-627)WLY009506993 | ||
| 035 | |a (WILEY)JSR13299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Sigurdardottir, Fjola D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insomnia symptoms and subclinical myocardial injury |b Data from the Nord‐Trøndelag Health (HUNT) study |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 European Sleep Research Society | ||
| 520 | |a Summary Insomnia symptoms are associated with increased risk of heart failure (HF) and cardiovascular (CV) mortality. We hypothesised that insomnia symptoms are cross‐sectionally associated with increased cardiac troponin I (cTnI), a biomarker of subclinical myocardial injury, and that phenotyping by insomnia symptoms and cTnI enhances longitudinal risk stratification in the general population. In a population‐based study, cTnI was measured in 8,398 participants (median age 49 years, 55% women), who had answered questionnaires regarding insomnia symptoms. Association between cTnI and insomnia symptoms was assessed by linear regression analysis for each response category of a sleep questionnaire. Insomnia symptoms were defined as having difficulty falling asleep almost every night, difficulty maintaining sleep almost every night, and/or non‐restorative sleep once a week or more. The primary outcome measure was a composite endpoint of CV mortality or first admission for HF. In all, 844 participants reported insomnia symptoms, 585 (69%) were women. Those with insomnia symptoms had marginally, but significantly higher median cTnI than those without insomnia symptoms, (median [interquartile range] 3.4 [2.4–5.2] ng/L versus 3.2 [2.2–4.9] ng/L; p = .014), but there was no association between any insomnia symptom and cTnI in unadjusted linear regression models (β 0.06, 95% confidence interval [CI] −0.01 to 0.12). In adjusted analyses, participants with insomnia symptoms and increased cTnI were at increased risk of the composite endpoint (hazard ratio 1.71, 95% CI 1.04–2.79) compared to participants with insomnia symptoms and low cTnI. In the general population, insomnia symptoms are not associated with biochemical evidence of subclinical myocardial injury. | ||
| 700 | 1 | |a Lyngbakken, Magnus N. |4 aut | |
| 700 | 1 | |a Hveem, Kristian |4 aut | |
| 700 | 1 | |a Hrubos Strøm, Harald |4 aut | |
| 700 | 1 | |a Røsjø, Helge |4 aut | |
| 700 | 1 | |a Redline, Susan |4 aut | |
| 700 | 1 | |a Omland, Torbjørn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Sleep Research |g 30(2021), 5 |w (DE-627)WLY009501215 |x 13652869 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2021 |g number:5 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.90 |q ASE |
| 951 | |a AR | ||
| 952 | |d 30 |j 2021 |e 5 |g 10 | ||